Doctor education aims to boost use of cheaper biologic drugs

This study tests whether offering doctors one-on-one educational meetings about biosimilar medications leads them to prescribe more biosimilars instead of the original brand-name drugs. About 1,325 clinicians who prescribe adalimumab will be randomly offered either an in-person or virtual educational visit or no visit at all. The goal is to see if this simple teaching approach can lower costs for patients and the healthcare system while maintaining effective treatment for autoimmune diseases like rheumatoid arthritis and psoriasis.